Australia markets open in 36 minutes
  • ALL ORDS

    7,357.70
    -23.40 (-0.32%)
     
  • AUD/USD

    0.6915
    -0.0000 (-0.00%)
     
  • ASX 200

    7,112.80
    -14.90 (-0.21%)
     
  • OIL

    90.59
    +0.09 (+0.10%)
     
  • GOLD

    1,771.60
    +0.40 (+0.02%)
     
  • BTC-AUD

    33,613.11
    -341.21 (-1.00%)
     
  • CMC Crypto 200

    558.74
    +1.01 (+0.18%)
     

This Blockbuster Drug from AbbVie Is Closer to Another Major Indication

·4-min read
This Blockbuster Drug from AbbVie Is Closer to Another Major Indication
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) recently adopted a positive opinion that recommended the approval of AbbVie's (NYSE: ABBV) Rinvoq for what would be its fifth indication in that market. This would be to treat patients with moderate-to-severe ulcerative colitis who had an inadequate response to conventional therapies or biologic agents. A decision for Rinvoq as a treatment for moderate-to-severe ulcerative colitis patients from the European Commission is expected in the third quarter of this year.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting